JOHNSON & JOHNSON

(JNJ)
  Report
Delayed Nyse  -  04:00 2022-08-09 pm EDT
170.18 USD   -0.01%
08/09Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Conference
BU
08/08Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceuticals, R&D, Johnson & Johnson
BU
08/08Johnson & Johnson Announces Executive Changes
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson's Unit Janssen Says EMA's Committee Backs Approval of Imbruvica to Treat Chronic Lymphocytic Leukemia

06/24/2022 | 09:02am EDT


© MT Newswires 2022
All news about JOHNSON & JOHNSON
08/09Johnson & Johnson to Participate in the Morgan Stanley 20th Annual Global Healthcare Co..
BU
08/08Mathai Mammen, M.D., Ph.D., Leaves Position as Executive Vice President, Pharmaceutical..
BU
08/08Johnson & Johnson Announces Executive Changes
CI
08/05The Janssen Pharmaceutical Companies - European Commission Approves IMBRUVICA (ibrutini..
AQ
08/05FOCUS : 5 Stocks for Yield Lovers
MS
08/04South Africa Health Regulator Flags First Death Linked to Johnson & Johnson COVID-19 Ja..
MT
08/04The Janssen Pharmaceutical Companies of Johnson & Johnson Announces European Commission..
CI
08/03DA Davidson Cuts Price Target on Johnson & Johnson to $190 From $196, Reiterates Buy/Ad..
MT
08/03Johnson & Johnson's Q2 Headwinds Pull Back Optimism on FY2022 Performance, D.A. Davidso..
MT
08/02Johnson & Johnson to Participate in the 2022 Wells Fargo Securities Healthcare Conferen..
BU
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 604 M - -
Net income 2022 21 415 M - -
Net cash 2022 10 065 M - -
P/E ratio 2022 20,8x
Yield 2022 2,58%
Capitalization 447 B 447 B -
EV / Sales 2022 4,57x
EV / Sales 2023 4,30x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 170,18 $
Average target price 185,55 $
Spread / Average Target 9,03%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-0.52%447 434
ELI LILLY AND COMPANY9.70%287 922
PFIZER, INC.-16.05%279 310
ROCHE HOLDING AG-16.02%275 991
ABBVIE INC.3.58%247 976
NOVO NORDISK A/S4.27%238 658